Last reviewed · How we verify
NCT03695822
Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome
Phase 4 trial testing Mirabegron 25mg in Overactive Bladder Syndrome. Withdrawn.
21 January 2019
Quick facts
| Lead sponsor | Far Eastern Memorial Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 24 December 2018 |
| Primary completion | 21 January 2019 |
| Estimated completion | 31 January 2019 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Mirabegron 25mg — full drug profile →
Conditions studied
- Overactive Bladder Syndrome — all drugs for Overactive Bladder Syndrome →
Sponsor
Far Eastern Memorial Hospital
Who can join
20 and older, female only, with Overactive Bladder Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
We will get the impact of mirabegron on psychological distress, urethra and bladder blood flow and c reactive protein.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03695822
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mirabegron 25mg
Trials testing the same drug.
- NCT07114640 — The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Func · Phase 3 · not yet recruiting
- NCT05040984 — Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome · unknown
- NCT03558919 — Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder · Phase 4 · completed
- NCT03059134 — Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan · Phase 3 · completed
- NCT04550702 — Predictors for Retreatement of OAB After DC Mirabegron · completed
Other recruiting trials for Overactive Bladder Syndrome
Currently open trials in the same condition.
- NCT05895045 — Yoga for Treatment of Overactive Bladder in Pediatric Patients · NA · recruiting
- NCT07081412 — Home-Based Transcutaneous Remotely Monitored Posterior Tibial Neuromodulation · NA · recruiting
- NCT07184307 — Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial · NA · recruiting
- NCT06546189 — Oral Lactobacillus Supplementation as Treatment for Overactive Bladder Syndrome: A Randomised Controlled Trial · NA · recruiting
- NCT06351683 — Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome · Phase 2 · recruiting
Other Far Eastern Memorial Hospital trials
Trials by the same sponsor.
- NCT07385976 — The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients · not yet recruiting
- NCT07107542 — Exploring the Relationship Between Mini-Clinical Evaluation Exercise (Mini-CEX) and Entrustable Professional Activities · not yet recruiting
- NCT07114653 — The Role of POLE Mutation in High Risk Endometrial Cancer. · recruiting
- NCT07105345 — Exploring Efficacy of Multi-Mode Cognitive Processing Therapy (CPT) for PTSD · NA · recruiting
- NCT07110350 — Clinical Outcomes of Non-Indicated Staged Laparotomies in Abdominal Trauma · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03695822 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Far Eastern Memorial Hospital
- Last refreshed: 7 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03695822.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing